Article
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
American journal of hematology - 1 Mar 2022
Reville Patrick K, Sasaki Koji, Kantarjian Hagop M, Daver Naval G, Yilmaz Musa, Dinardo Courtney D, Short Nicholas J, Borthakur Gautam, Pemmaraju Naveen, Mehta Rohtesh S, Pierce Sherry, Konoplev Sergej N, Khoury Joseph D, Garcia-Manero Guillermo, Konopleva Marina Y, Jabbour Elias, Ravandi Farhad, Kadia Tapan M
Abstract excerpt
Mutations in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those with high allelic ratio (AR). Current AML treatment strategies, including high dose cytarabine, purine analogs, FLT3 inhibitors (FLT3i), and with or without allogeneic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.